Charles River Laboratories International (NYSE:CRL) Sets New 1-Year High at $324.31

Charles River Laboratories International, Inc. (NYSE:CRL)’s stock price reached a new 52-week high on Monday . The stock traded as high as $324.31 and last traded at $323.01, with a volume of 2959 shares trading hands. The stock had previously closed at $323.38.

Several equities analysts have recently weighed in on the company. Zacks Investment Research cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Monday. Credit Suisse Group lifted their price objective on Charles River Laboratories International from $259.00 to $301.00 and gave the company a “neutral” rating in a report on Thursday, February 18th. Argus lifted their price objective on Charles River Laboratories International from $235.00 to $265.00 and gave the company a “buy” rating in a report on Tuesday, December 22nd. Truist lifted their price objective on Charles River Laboratories International from $256.00 to $324.00 in a report on Thursday, February 18th. Finally, Deutsche Bank Aktiengesellschaft lifted their target price on Charles River Laboratories International from $250.00 to $334.00 and gave the company a “buy” rating in a research report on Thursday, February 25th. Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $260.80.

The stock has a market cap of $16.19 billion, a price-to-earnings ratio of 53.73, a price-to-earnings-growth ratio of 2.19 and a beta of 1.12. The company has a 50-day simple moving average of $292.53 and a two-hundred day simple moving average of $262.86. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.22 and a current ratio of 1.45.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Tuesday, February 16th. The medical research company reported $2.39 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.28. Charles River Laboratories International had a return on equity of 22.41% and a net margin of 10.68%. The company had revenue of $790.99 million during the quarter, compared to the consensus estimate of $755.98 million. As a group, sell-side analysts predict that Charles River Laboratories International, Inc. will post 7.87 earnings per share for the current fiscal year.

In other news, CEO James C. Foster sold 30,000 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 11th. The stock was sold at an average price of $285.02, for a total transaction of $8,550,600.00. Following the completion of the transaction, the chief executive officer now directly owns 255,041 shares in the company, valued at approximately $72,691,785.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO James C. Foster sold 37,731 shares of the business’s stock in a transaction on Tuesday, February 23rd. The shares were sold at an average price of $281.27, for a total value of $10,612,598.37. Following the completion of the sale, the chief executive officer now owns 221,151 shares of the company’s stock, valued at $62,203,141.77. The disclosure for this sale can be found here. Insiders have sold a total of 107,518 shares of company stock valued at $30,932,255 over the last quarter. 1.90% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CRL. Schonfeld Strategic Advisors LLC bought a new stake in Charles River Laboratories International in the 3rd quarter valued at $1,642,000. Jeppson Wealth Management LLC bought a new stake in shares of Charles River Laboratories International during the 3rd quarter valued at $29,000. Townsquare Capital LLC lifted its position in shares of Charles River Laboratories International by 10.4% during the 3rd quarter. Townsquare Capital LLC now owns 5,583 shares of the medical research company’s stock valued at $1,303,000 after acquiring an additional 527 shares during the period. Brinker Capital Investments LLC bought a new stake in shares of Charles River Laboratories International during the 3rd quarter valued at $930,000. Finally, Wetherby Asset Management Inc. bought a new stake in shares of Charles River Laboratories International during the 3rd quarter valued at $433,000. Institutional investors and hedge funds own 92.30% of the company’s stock.

About Charles River Laboratories International (NYSE:CRL)

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Story: FinTech

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.